KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial.

Yanchun Meng, Yingying Liu, Mingxi Lin, Lili Wang, Yuxin Mu, Ling Yang, Yiqun Du, Xiaojun Liu, Yong Chen, Shaodong Tian, Qin Zhou, Xiaojie Zhuang, Zikang Li, Jinsong Liu, Shencun Fang, Weifei Fan, Yu Mao, Ling Zhang, Hao Wu, Fei Yan, Jie Weng, Jianhua Zhao, Xiangyu Long, Lianfang Liu, Jianbo Zhou, Jian Zhang

J Clin Oncol JCO2601029

PMID42241642
PMCID-
DOI10.1200/JCO-26-01029
发表日期2026-06-04
摘要

摘要

PURPOSE: Guideline-recommended 4-day dexamethasone (DEX) for highly emetogenic chemotherapy (HEC) raises toxicity and immunotherapy interference concerns. We tested whether DEX reduction or omission with netupitant/palonosetron (NEPA) plus olanzapine (OLZ) is noninferior to standard DEX. PATIENTS AND METHODS: In this open-label, randomized phase III noninferiority trial across 28 Chinese centers, adults receiving HEC received NEPA (day 1) plus OLZ (days 1-4) and were randomly assigned to standard DEX (12 mg day 1, 8 mg days 2-4), DEX-sparing (6 mg day 1 only), or DEX-free (no DEX). The primary end point was complete response (CR; no emesis/no rescue medication) from 0 to 120 h. Noninferiority margin was -12% (one-sided α = .025). RESULTS: Of 644 randomly assigned patients (median age 54.9 years; 66.0% female), stratified analysis showed overall CR rates of 72.4% for standard, 72.2% for DEX-sparing (stratified risk difference [RD], -0.2% [95% CI, -8.7 to 8.5]; Pnoninferiority = .005), and 70.1% for DEX-free (stratified RD, -2.2% [95% CI, -10.7 to 6.4]; Pnoninferiority = .014). Both met noninferiority, confirmed in per-protocol analysis. Steroid-related toxicities were significantly lower with DEX-sparing and DEX-free regimens versus standard. CONCLUSION: NEPA plus OLZ with reduced (6 mg day 1 only) or no DEX is noninferior to standard 4-day DEX for chemotherapy-induced nausea and vomiting prevention in HEC, supporting steroid-sparing strategies particularly relevant in the chemo-immunotherapy era.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。